SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Essex enriches and complements Emmes’ services
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Time to combine innovation, access and technology to deliver positive patient outcomes
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Clinical studies are expected to start in Q2 2023.
This artificial RNA ligase has higher thermostability than natural RNA ligase
Subscribe To Our Newsletter & Stay Updated
